Want to see AU:DXB full AI Analyst Report?
DXB Stock Chart & Stats
AU$0.29
>-AU$0.01(-2.00%)
At close: 4:00 PM EDT
AU$0.29
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.16 - AU$0.67
Previous CloseN/A
Volume265.68K
Average Volume (3M)698.75K
Market Cap
AU$123.08M
Enterprise ValueAU$107.16M
Total Cash (Recent Filing)AU$16.15M
Total Debt (Recent Filing)AU$232.09K
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding600,396,800
10 Day Avg. Volume492,936
30 Day Avg. Volume698,748
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-8.34
Price to Sales (P/S)28.29
P/FCF Ratio-2.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$9.00M
Bulls Say, Bears Say
Bulls Say
Low Debt BurdenLow leverage reduces the immediate burden of debt service and lowers insolvency risk compared with a highly indebted business. This gives Dimerix greater flexibility to direct available capital toward clinical development and partnering activities, although it does not remove funding needs.
High Gross Profit Relative To RevenueA high gross-profit relationship suggests the underlying drug-development and licensing model can retain meaningful value after direct costs when revenue is generated. If revenue becomes more consistent, this structure could provide operating leverage as development spending is managed over time.
Focused Lead Drug ProgramConcentrating resources on a lead therapy and defined renal indications can support focused clinical execution, clearer partnering priorities, and efficient use of a small workforce. Progress in DMX-200 could create several future income routes, including licensing, milestones, royalties, or product sales.
Bears Say
Persistent Deep LossesRecurring operating and net losses show that Dimerix has not yet demonstrated a self-sustaining earnings model. Continued losses can consume capital, constrain investment choices, and increase dependence on successful development outcomes or external financing to support the pipeline.
Unstable Revenue TrendThe sharp reversal after the 2025 revenue rebound indicates that income is not yet following a durable growth trajectory. Unpredictable revenue makes planning more difficult, weakens confidence in near-term operating leverage, and leaves future performance highly dependent on development or partnering events.
Cash Burn And Negative EquityHeavy cash consumption and negative equity materially reduce financial resilience, even though debt is generally low. The combination suggests ongoing funding needs and less capacity to absorb setbacks, making continued access to financing or successful partner support important for sustaining development.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.16 and its highest was AU$0.67 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$123.08M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 01, 2027 which is in 129 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 26, 2026. The company reported -AU$0.023 earnings per share for the quarter.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Overvalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.023 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:DXB Sentiment 91%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.81%
12-Months-Change
Fundamentals
Return on Equity
362.74%
Trailing 12-Months
Asset Growth
-35.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dimerix Limited
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Technical Analysis
Actinogen Medical
―
Alterity Therapeutics
―
Immutep Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―